Foresee Pharmaceuticals reports positive Phase 1 trial results for Linvemastat

By on    Pharma Industry News  

Foresee Pharmaceuticals reports positive Phase 1 trial results for Linvemastat

Foresee Pharmaceuticals (TPEx: 6576) has reported successful preliminary results from its Phase 1 clinical trial of linvemastat (FP-020), an innovative and selective matrix metalloproteinase-12 (MMP-12) inhibitor. Conducted in Australia, the trial aimed to assess the safety, tolerability, and pharmacokinetics (PK) of ascending doses of linvemastat in healthy volunteers. The study marks a significant milestone in […]

Foresee Pharmaceuticals begins FP-025 phase 2/3 trial in Covid-19 associated ARDS

By on    Pharma Industry News  

Foresee Pharmaceuticals begins FP-025 phase 2/3 trial in Covid-19 associated ARDS

Foresee Pharmaceuticals has started patient dosing in a phase 2/3 trial of FP-025 in adults having severe to critical Covid-19 with associated acute respiratory distress syndrome (ARDS). According to the Taiwanese pharma company, FP-025 is an oral small molecule inhibitor of MMP-12, whose main functions are the modulation of various components such as elastin and […]